Harm Reduction Therapeutics Inc.

Harm Reduction Therapeutics Inc. (HRT) is not a conventional grantmaking foundation, and grant seekers should not approach it as one. IRS Business Master File data flags it as a grantmaker under NTEE code F20 (substance abuse prevention), but its own Form 990 filings report $0 in grants paid to other organizations in every year on record (2019-2023). HRT is instead an operating 501(c)(3) nonprofit pharmaceutical company — the first of its kind — that developed and now manufactures RiVive, an FDA-approved (August 2023) over-the-counter naloxone nasal spray, and sells it at cost with no profit to the organization, its directors, or employees. What the IRS data labels 'total giving' ($1.86M-$9.74M across 2019-2023) is overwhelmingly R&D, clinical, manufacturing, and distribution program spending on RiVive itself, not third-party grant disbursements. Founded in 2017 by John Pinney (Chairman) and Michael Hufford (President/CEO), HRT runs lean: three of five listed officers (Judy Ashworth, Chief Medical Officer; Bernie Simone, Treasurer/COO; and directors Elliott Millenson and James Williams) draw $0 compensation, and Hufford's own reported compensation has ranged from $30,000 to $120,000 across filings — signaling a small, mission-driven team rather than a large grants administration staff. For organizations genuinely seeking support, the real entry points are: (1) product access through Remedy Alliance/For The People, HRT's established partner distributing at least 10% of annual RiVive production free to harm reduction programs (already serving 200+ programs across 44 states plus D.C.); (2) a direct financial-support inquiry to financialsupport@harmreductiontherapeutics.org describing a specific naloxone-access gap; or (3) bulk purchase at cost through HRT's direct ordering portal or wholesale distributors (Cardinal Health, Cencora, McKesson) for organizations with budget but needing lower unit cost than commercial competitors like Narcan. There is no LOI-to-full-proposal cycle, review committee, or site-visit process — relationships form through informal email/phone contact and existing distribution partnerships, not a grants pipeline.

HRT's financials read as a product-development nonprofit scaling toward and through FDA approval, not a grantmaking budget. Total assets grew from $1.56M (FY2019) to $8.34M (FY2024), while total revenue swung sharply year to year: $1.55M (2019), $9.0M (2020), effectively $0/nominal $1 (2021 — likely a contribution-timing gap in the filing), $11.0M (2022), $3.13M (2023), and $6.93M (2024). Contributions received tracked this pattern closely — $1.55M (2019), $9.0M (2020), $0 (2021), $11.0M (2022), and $9.08M (2023) — consistent with large, lumpy charitable gifts (including Purdue Pharma bankruptcy-settlement funding of up to $9M approved in March 2023) rather than steady annual fundraising. Critically, grants_paid to other organizations was $0 in every filed year (2019-2023), and the top-grantee dataset for this record is empty — there is no median grant size, grant range, or program-area breakdown to report because HRT does not make cash grants to outside organizations. Instead, 'total_giving' in the 990 data ($1.86M in 2019 rising to a peak of $9.74M in 2022, then $2.87M in 2023) represents HRT's own program service expenses: clinical trials, FDA approval costs, and manufacturing/distribution of RiVive. Officer compensation totals were modest and volatile — $50,656 (2021) to $257,386 (2023) across all listed officers combined — reflecting a small operating team that grew modestly as the organization moved from R&D into commercial distribution. Geographically, HRT is headquartered in Bethesda, MD, but its actual impact is national: RiVive donations flow through Remedy Alliance's network spanning 44 states and D.C., and commercial distribution runs through national wholesalers (Cardinal Health, Cencora, McKesson) plus retail shelves as of mid-2026. There is no evidence of state-restricted or regionally targeted giving.

HRT sits in the middle of this $7M-$10M asset peer band by size, but it is structurally distinct from all five peers: the comparison set is drawn from the IRS Health/NTEE category and asset range, and while detailed giving data for the peer foundations isn't available in this record, none of the peer names or web presence suggest they operate as product-development nonprofits — they read as conventional family or community health foundations more likely to run traditional grant cycles. Grant seekers evaluating this peer set should treat HRT as an outlier requiring a partnership/product-access pitch, while approaching the other five with standard LOI-based grant research.

HRT's most recent public activity centers on distribution partnerships rather than new grantmaking. On March 19, 2026, HRT announced a partnership with Capstone Health Alliance to expand nationwide naloxone access. On April 21, 2026, it released its 2025 RiVive Community Feedback Report (following an April 7, 2025 report covering 2024), documenting how donated and distributed doses were used by partner programs. By mid-2026, RiVive reached full nationwide retail shelf availability, competing alongside Emergent BioSolutions' Narcan and a newly FDA-approved third entrant, Rextovy from Amphastar Pharmaceuticals (approved June 2026) — intensifying competition in the OTC naloxone space and likely reinforcing HRT's at-cost/nonprofit pricing as its key differentiator going forward. Earlier, in August 2024, HRT struck a strategic partnership with A2A Alliance Pharmaceuticals to expand OTC naloxone access specifically to U.S. federal entities and veterans, and in March 2024 it partnered with the Drug Intervention Institute to provide discounted RiVive via ONEbox distribution kits. Separately but relevantly, federal policy shifted in this window: an April 2026 SAMHSA letter updated July 2025 guidance to de-emphasize 'harm reduction' as a funding framework nationally, even as naloxone-specific interventions continued to receive federal support — a signal that organizations citing federal alignment in outreach to HRT should watch SAMHSA's evolving terminology. No leadership changes were identified in the available research; John Pinney (Chairman) and Michael Hufford (President/CEO/Secretary) remain the organization's founders and named leadership per its most recent Form 990 filings.

There is no grant application, LOI form, or portal at Harm Reduction Therapeutics — treating this like a standard foundation proposal will go nowhere. Instead, match your ask to the right channel: (1) If you run a harm reduction program and need free naloxone doses, do not email HRT directly first — go to Remedy Alliance/For The People (info@remedyallianceftp.org), HRT's designated partner for distributing at least 10% of annual RiVive production free of charge; Remedy Alliance already serves 200+ programs in 44 states and D.C., so joining that existing network is a faster path than a cold approach to HRT. (2) If you need charitable/financial support tied specifically to naloxone access (not a general operating grant), email financialsupport@harmreductiontherapeutics.org with a concise, specific description of your population served, current supply gap, and requested volume — HRT's filings show it does not disburse discretionary cash grants, so frame the ask around naloxone access, not general funding. (3) If your organization has budget and simply needs lower unit cost than commercial naloxone brands, register for a direct customer account (order portal) or purchase through Cardinal Health, Cencora, or McKesson in case lots of 24 twin packs — this is a purchasing relationship, not a grant. (4) Federal agencies and veteran-serving organizations should reference the August 2024 A2A Alliance Pharmaceuticals partnership as a precedent when reaching out, since HRT has already built a channel for that use case. The most common mistake seekers will make is submitting a formal multi-page grant narrative or 990-style budget — HRT's own reported grants-paid figure has been $0 every year on file, so a lengthy proposal will likely be redirected or ignored. Keep initial outreach to a short email (a few paragraphs) covering who you are, who you serve, and what specifically you need (doses vs. dollars vs. discounted purchase), and follow up by phone at (888) 412-7454 if there's no response within a couple of weeks. Building a relationship through Remedy Alliance's existing network is the single highest-leverage move available to a harm reduction program seeking product support from HRT.